JP2006500958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500958A5 JP2006500958A5 JP2005501198A JP2005501198A JP2006500958A5 JP 2006500958 A5 JP2006500958 A5 JP 2006500958A5 JP 2005501198 A JP2005501198 A JP 2005501198A JP 2005501198 A JP2005501198 A JP 2005501198A JP 2006500958 A5 JP2006500958 A5 JP 2006500958A5
- Authority
- JP
- Japan
- Prior art keywords
- rna molecule
- cancer
- igfbp
- target gene
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 claims 4
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 claims 4
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims 4
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims 4
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 102000003780 Clusterin Human genes 0.000 claims 3
- 108090000197 Clusterin Proteins 0.000 claims 3
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 claims 2
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940102223 injectable solution Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 101150087532 mitF gene Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40519302P | 2002-08-21 | 2002-08-21 | |
| US60/405,193 | 2002-08-21 | ||
| US40815202P | 2002-09-03 | 2002-09-03 | |
| US60/408,152 | 2002-09-03 | ||
| US47238703P | 2003-05-20 | 2003-05-20 | |
| US60/472,387 | 2003-05-20 | ||
| PCT/CA2003/001277 WO2004018676A2 (en) | 2002-08-21 | 2003-08-21 | Rnai probes targeting cancer-related proteins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010128382A Division JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2010250838A Division JP5662766B2 (ja) | 2002-08-21 | 2010-11-09 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006500958A JP2006500958A (ja) | 2006-01-12 |
| JP2006500958A5 true JP2006500958A5 (enExample) | 2006-09-07 |
| JP4717633B2 JP4717633B2 (ja) | 2011-07-06 |
Family
ID=31950539
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501198A Expired - Fee Related JP4717633B2 (ja) | 2002-08-21 | 2003-08-21 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2010250838A Expired - Fee Related JP5662766B2 (ja) | 2002-08-21 | 2010-11-09 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010128382A Expired - Fee Related JP5171887B2 (ja) | 2002-08-21 | 2010-06-04 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2010250838A Expired - Fee Related JP5662766B2 (ja) | 2002-08-21 | 2010-11-09 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| JP2013067754A Pending JP2013150624A (ja) | 2002-08-21 | 2013-03-28 | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US8252918B2 (enExample) |
| EP (2) | EP1532249A2 (enExample) |
| JP (4) | JP4717633B2 (enExample) |
| KR (3) | KR101238701B1 (enExample) |
| AU (1) | AU2003258426B2 (enExample) |
| CA (2) | CA2494766C (enExample) |
| IL (3) | IL166658A (enExample) |
| NO (2) | NO334573B1 (enExample) |
| NZ (1) | NZ552872A (enExample) |
| WO (1) | WO2004018676A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| CA2469685C (en) | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| KR101238701B1 (ko) * | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| CA2494764C (en) * | 2002-08-21 | 2013-04-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| US7635673B2 (en) | 2003-03-25 | 2009-12-22 | The Board Of Trustees Of The University Of Illinois | Methods of inhibiting tumor cell proliferation |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US20050019918A1 (en) * | 2003-06-03 | 2005-01-27 | Hidetoshi Sumimoto | Treatment of cancer by inhibiting BRAF expression |
| JP2005013221A (ja) * | 2003-06-03 | 2005-01-20 | Keio Gijuku | Ｂｒａｆ発現抑制を利用した癌の治療 |
| CN101389345A (zh) * | 2004-03-19 | 2009-03-18 | 宾州研究基金会 | 治疗黑素瘤的组合方法和组合物 |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| EP2298896A1 (en) * | 2004-06-22 | 2011-03-23 | The Board of Trustees of the University of Illinois | Methods of inhibiting tumor cell proliferation with FOXM1 siRNA |
| CA3147177A1 (en) * | 2004-07-23 | 2006-02-02 | Pacific Edge Limited | Urine markers for detection of bladder cancer |
| WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
| US8044179B2 (en) | 2005-09-13 | 2011-10-25 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| US8029980B2 (en) | 2006-09-29 | 2011-10-04 | The Board Of Trustees Of The University Of Illinois | Identification and use of agents that modulate oncogenic transcription agent activity |
| WO2008088836A2 (en) * | 2007-01-16 | 2008-07-24 | The Burnham Institute For Medical Research | Compositions and methods for treatment of colorectal cancer |
| US8071752B2 (en) | 2007-01-29 | 2011-12-06 | City Of Hope | Multi-targeting short interfering RNAs |
| US20100112687A1 (en) * | 2007-03-02 | 2010-05-06 | Mdrna, Inc. | Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| US8217161B2 (en) * | 2008-04-22 | 2012-07-10 | Clemson University Research Foundation | Methods of inhibiting multiple cytochrome P450 genes with siRNA |
| ES2734886T3 (es) | 2009-11-24 | 2019-12-12 | Alethia Biotherapeutics Inc | Anticuerpos anti-clusterina y fragmentos de unión a antígeno y su uso para reducir el volumen tumoral |
| DK2673363T3 (da) | 2011-02-11 | 2017-11-13 | Univ Rockefeller | Behandling af angiogenesesygdomme |
| NZ626742A (en) | 2012-02-22 | 2016-06-24 | Alethia Biotherapeutics Inc | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
| CN106282185B (zh) * | 2016-08-18 | 2020-06-26 | 广州市锐博生物科技有限公司 | 一种用于抑制簇集蛋白基因表达的成套siRNA及其应用 |
| WO2024214933A1 (ko) * | 2023-04-13 | 2024-10-17 | 한양대학교 에리카산학협력단 | 인산화된 igfbp5의 과도한 생성을 차단하여 암을 예방 또는 치료하는 방법 |
| WO2025041340A1 (ja) * | 2023-08-24 | 2025-02-27 | 株式会社Dti | 二重特異性核酸 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5736580A (en) * | 1980-08-13 | 1982-02-27 | Hitachi Ltd | Protecting method for converter |
| EP0575518A1 (en) * | 1991-03-06 | 1993-12-29 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US20020086386A1 (en) * | 1997-03-04 | 2002-07-04 | Kamb Carl Alexander | B-catenin assays, and compositions therefrom |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| IL144975A0 (en) | 1999-02-26 | 2002-06-30 | Univ British Columbia | A composition containing an antisense oligonucleotide |
| WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
| ATE393220T1 (de) * | 1999-07-19 | 2008-05-15 | Univ British Columbia | Antisense-therapie für hormonregulierte tumoren |
| US6140126A (en) * | 1999-10-26 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of Y-box binding protein 1 expression |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| WO2002081628A2 (en) * | 2001-04-05 | 2002-10-17 | Ribozyme Pharmaceuticals, Incorporated | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| CA2403397A1 (en) * | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| DK2796553T3 (da) * | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| HU229207B1 (en) * | 2000-09-14 | 2013-09-30 | Univ British Columbia | Antisense insulin-like growth factor binding protein (igfbp)-2-oligodeoxynucleotides for prostate and other endocrine regulated tumor therapy |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| EP1354038A2 (en) | 2000-12-28 | 2003-10-22 | J & J Research Pty Ltd | Double-stranded rna-mediated gene suppression |
| CA2469685C (en) * | 2002-01-17 | 2013-03-12 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| KR101238701B1 (ko) * | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| CA2494764C (en) * | 2002-08-21 | 2013-04-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
-
2003
- 2003-08-21 KR KR1020117025408A patent/KR101238701B1/ko not_active Expired - Fee Related
- 2003-08-21 AU AU2003258426A patent/AU2003258426B2/en not_active Ceased
- 2003-08-21 EP EP03792075A patent/EP1532249A2/en not_active Ceased
- 2003-08-21 CA CA2494766A patent/CA2494766C/en not_active Expired - Fee Related
- 2003-08-21 CA CA2882443A patent/CA2882443C/en not_active Expired - Fee Related
- 2003-08-21 JP JP2005501198A patent/JP4717633B2/ja not_active Expired - Fee Related
- 2003-08-21 KR KR1020057002963A patent/KR101212512B1/ko not_active Expired - Fee Related
- 2003-08-21 NZ NZ552872A patent/NZ552872A/en not_active IP Right Cessation
- 2003-08-21 WO PCT/CA2003/001277 patent/WO2004018676A2/en not_active Ceased
- 2003-08-21 US US10/646,436 patent/US8252918B2/en not_active Expired - Fee Related
- 2003-08-21 KR KR1020107028249A patent/KR101117673B1/ko not_active Expired - Fee Related
- 2003-08-21 EP EP10010458.7A patent/EP2263679B1/en not_active Expired - Lifetime
-
2005
- 2005-02-02 IL IL166658A patent/IL166658A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051423A patent/NO334573B1/no not_active IP Right Cessation
-
2006
- 2006-02-23 US US11/276,300 patent/US7964717B2/en not_active Expired - Fee Related
-
2008
- 2008-05-06 US US12/116,083 patent/US7820635B2/en not_active Expired - Fee Related
-
2009
- 2009-02-22 IL IL197159A patent/IL197159A/en not_active IP Right Cessation
-
2010
- 2010-06-04 JP JP2010128382A patent/JP5171887B2/ja not_active Expired - Fee Related
- 2010-07-28 US US12/845,521 patent/US8759308B2/en not_active Expired - Fee Related
- 2010-11-09 JP JP2010250838A patent/JP5662766B2/ja not_active Expired - Fee Related
-
2012
- 2012-02-24 US US13/404,741 patent/US9487777B2/en not_active Expired - Fee Related
- 2012-09-14 NO NO20121038A patent/NO337130B1/no not_active IP Right Cessation
-
2013
- 2013-03-28 JP JP2013067754A patent/JP2013150624A/ja active Pending
-
2014
- 2014-06-24 IL IL233352A patent/IL233352A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500958A5 (enExample) | ||
| Boer et al. | DNA-binding drugs caught in action: the latest 3D pictures of drug-DNA complexes | |
| Sharma et al. | Versatility of peptide nucleic acids (PNA s): Role in chemical biology, drug discovery, and origins of life | |
| Gryaznov | Oligonucleotide N3′→ P5′ phosphoramidates as potential therapeutic agents | |
| Tyler et al. | Peptide nucleic acids targeted to the neurotensin receptor and administered ip cross the blood–brain barrier and specifically reduce gene expression | |
| Dragulescu-Andrasi et al. | Cell-permeable peptide nucleic acid designed to bind to the 5 ‘-untranslated region of E-cadherin transcript induces potent and sequence-specific antisense effects | |
| RU2006126643A (ru) | Олигомерные соединения для модуляции bcl-2 | |
| Pradeep et al. | Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics | |
| Wang et al. | Peptide nucleic acid (PNA) binding-mediated gene regulation | |
| WO2004018676A3 (en) | Rnai probes targeting cancer-related proteins | |
| JP2008540363A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2010512747A5 (enExample) | ||
| Rahman et al. | Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates | |
| Fong et al. | Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family | |
| RU2001124840A (ru) | Противоопухолевые антисмысловые последовательности, направленные на компоненты r1 и r2 рибонуклеотидредуктазы | |
| JP2005517412A5 (enExample) | ||
| JP2013537404A5 (enExample) | ||
| Lown | Lexitropsins in antiviral drug development | |
| Yu et al. | Orthogonal γPNA dimerization domains empower DNA binders with cooperativity and versatility mimicking that of transcription factor pairs | |
| JP2019523302A5 (enExample) | ||
| RU2008125041A (ru) | миРНК ПРОТИВ МИОЗИНА VA И ДЕПИГМЕНТАЦИЯ КОЖИ | |
| Chen | Clinical development of antisense oligonucleotides as anti-cancer therapeutics | |
| Jaschinski et al. | Design and selection of antisense oligonucleotides targeting transforming growth factor beta (TGF-β) isoform mRNAs for the treatment of solid tumors | |
| Svahn et al. | Adding functional entities to plasmids |